Collectively, our findings elucidate ARID1A as a critical regulator of SCLC pathogenesis through its dual control of proliferation and genomic stability while revealing novel therapeutic vulnerabilities that can be exploited through ARID1A-targeting strategies and BET inhibitor combinations. This evidence concerns the gene ARID1A and small cell lung carcinoma.